Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo

Novo Nordisk Stock Climbs Over 4% In Friday Pre-Market: What's Going On?

Shares of Novo Nordisk A/S (NYSE:NVO) climbed 4.29% during Friday’s pre-market trading session, after rival Eli Lilly (NYSE:LLY)’s Phase 3 ATTAIN-1 trial for obesity drug, orforglipron, trailed the Danish drug giant’s semaglutide on Thursday.

Benzinga

This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.

Barchart

‘Shock’ as study reveals how weight-loss pill stacks up against injections

Shares in a pharmaceutical company plummeted after the results were made public

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Ozempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish kroner), missing the consensus of $11.79 billion.

Benzinga

Novo Nordisk keeps growing, fuelling hopes of a stock rebound

Novo Nordisk reported 18% sales growth in the first half of 2025, despite a profit warning that triggered a record share drop. Goldman Sachs says the sell-off is overdone and analysts highlight a potential buying opportunity.

Euronews

Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign of deeper trouble ahead?

Barchart

Will Hims & Hers Fall Along With Novo Nordisk?

Novo Nordisk shares are trading as low as 35% of their 52-week highs, making Hims & Hers investors nervous whether a selloff is coming.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57.

Benzinga

Trump officials plan coverage for weight loss drugs under Medicare and Medicaid

Pilot program, first pitched under Biden, will cover GLP-1 drugs such as Ozempic to address chronic obesity in US

The Guardian - US

Should You Buy the Post-Earnings Plunge in Novo Nordisk Stock or Stay Far, Far Away?

Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower over the next 12 months?

Barchart

Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS'

Weight-loss drugmaker Novo Nordisk A/S (NYSE:NVO)’s technical chart is displaying a largely bearish trend amid a profit warning issued by the company tied to its blockbuster obesity drug Wegovy. However, this expert believes that the Danish pharmaceutical giant could have avoided some trouble if it hadn’t ended its partnership with…

Benzinga

Novo Nordisk Cuts Earning Forecasts Again, Names New CEO

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its earning forecasts again as it unveiled a new chief executive to tackle "recent market challenges".

International Business Times

Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Evening Standard

Novo Nordisk shares plummet over 20% on weight-loss drug sale slump

The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.

Euronews

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Novo Nordisk Implodes After Wegovy Warning—Is The Weight-Loss Bubble Bursting?

Novo Nordisk A/S (NYSE:NVO) suffered its worst trading session on record Tuesday, plunging as much as 25% in European markets after issuing a surprise profit warning tied to its blockbuster obesity drug Wegovy and appointing a new CEO.

The Independent UK

Weight-loss jab Wegovy sees another prescription boost after ban on copycats

Novo CEO ousted in May, in place until successor named

Benzinga

Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case

The Novo Nordisk A/S (NYSE:NVO) attempt to block Mylan Pharmaceuticals from launching a generic version of its weight-loss drug Wegovy hit a major obstacle as the court ruled in Mylan's favor on key infringement claims related to U.S. Patent No. 9,764,003.

Kiplinger

Wellness Stocks to Invest in Now

Breakthroughs that help us live longer, healthier lives can also create opportunities for investors.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Obesity drug prices are dropping, but getting a steady supply remains a challenge

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging

Benzinga

HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?

Telehealth darling Hims Hers Health Inc (NYSE:HIMS) got slapped with a 34% stock crash on Monday. Novo Nordisk A/S (NYSE:NVO) ended their relationship – and it wasn't amicable.

International Business Times UK

Why Did Novo Nordisk Pull the Plug on Hims Collaboration?

Novo Nordisk ended its partnership with Hims & Hers on 23 June 2025, accusing the telehealth firm of selling unsafe, unapproved Wegovy knock-offs. Hims' stock tanked, and legal risks loom.

The Independent UK

Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug

Hims & Hers had partnered with the Danish pharmaceutical giant in April to sell Wegovy

Fortune

Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee

“I’m sure someone’s lost their job,” said the CEO of Sandoz, which has now filed to launch a generic GLP-1 drug in Canada next year.

MarketBeat

With Novo Nordisk's CEO Out, Wall Street Wants an American Leader

With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?

The Independent UK

Wegovy use spikes among teens as doctors grapple with obesity crisis

New data indicates that American teenagers are increasingly using the weight-loss drug Wegovy, as confidence in its use for young people with obesity grows among families and doctors.

1 2 3 4 5

People

Lars Fruergaard Jørgensen

18 stories

David Ricks

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Regeneron Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.